On October 26, U.S. spot Bitcoin exchange-traded funds (ETFs) experienced net inflows of $110 million, driven entirely by BlackRock’s iShares Bitcoin Trust. In contrast, Ether ETFs recorded net outflows totaling $88.58 million, despite Fidelity’s Ether ETF bringing in $16.13 million. These net flow figures represent the balance of money moving in and out of the funds but do not specify individual buyer or seller identities. The data highlights differing investor interest levels between Bitcoin and Ether ETFs on that day.
The U.S. spot Bitcoin ETFs saw net inflows of $110 million on October 26, while Ether ETFs experienced net outflows of $88.58 million. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 28, 2026 20:03 WIB: out of 50 major cryptocurrencies priced on Pluang, 41 rose and 8 fell today. Notable movers include SXP (Solar) down 46.27% to Rp37, BAL (Balancer) up 11.14% to Rp16,297, and EOS (EOS.IO) up 8.13% to Rp12,649, with typical hold times ranging from 85 to 94 days.
On National First Responders Day, ADT celebrated local first responders and its monitoring professionals by unveiling a renovated monitoring center in Irving, Texas, part of a $2 million investment. The upgraded center features enhanced equipment and...
Cobalt Boats unveiled the 2027 265 Coastal Edition, a fully redesigned luxury outboard runabout tailored for coastal boating enthusiasts. Featuring wood-free construction, enhanced comfort, and advanced technology like dual 9-inch displays and option...
Presidio was named Enterprise Partner of the Year and Software and Services Partner of the Year for the Americas at the Cisco Partner Summit 2026. These awards recognize partners who excel in service and innovation, helping customers succeed through ...
Air Canada and CAE announced the opening of applications on November 1, 2026, for the 2027 Commandante-Judy-Cameron scholarships. These scholarships support up to eight Canadian women pursuing professional pilot or aircraft maintenance technician tra...
Arcutis Biotherapeutics has appointed Dr. Rob Scott, a seasoned pharmaceutical executive with over 40 years of experience, to its Board of Directors. Dr. Scott's expertise in developing and securing approvals for innovative medicines, including derma...
